Health and Personal Care Retailers (U.S.) — NAICS 4561

A Histometrics rollup primer for both public-market and private investors. NAICS = North American Industry Classification System, the U.S. government's standard scheme for sorting businesses by their primary activity. This page covers the four-digit industry group 4561 and synthesizes across its four child industries; for the deep dives, follow the linked leaf primers.

---

1. Overview

NAICS 4561 is the store-based "health, wellness, and grooming" aisle of American retail — the specialty stores (physical and online) where consumers buy the goods that keep them medicated, well, good-looking, and able to see. It is one of retail's most defensive corners because so much of what it sells is non-negotiable: a prescription refill, a hearing aid, a pair of eyeglasses. But it is also one of retail's most internally divided corners. Underneath a single four-digit code sit four businesses with almost nothing in common about how they make money, who owns them, or which way they are growing.

The four children are:

• 45611 — Pharmacies and Drug Retailers: the CVS/Walgreens/independent-drugstore world. By far the giant of the group — roughly 83% of the level's sales [1][2].
• 45612 — Cosmetics, Beauty Supplies, and Perfume Retailers: Ulta, Sephora, Sally, and thousands of neighborhood beauty-supply shops [3].
• 45613 — Optical Goods Retailers: LensCrafters, America's Best, Warby Parker, and the independent optician [4].
• 45619 — Other Health and Personal Care Retailers: the "everything-else" tier — vitamin/supplement shops plus hearing-aid centers and home-medical-equipment dealers [5].

The single most important fact about this level is that it is really the pharmacy industry wearing a broader label, with three much smaller, very different businesses attached. Pharmacies dominate the dollars, set the concentration statistics, and carry the level's biggest policy story (drug-reimbursement pressure). The other three children matter to investors precisely because they behave differently — beauty is a growing, high-loyalty discretionary business; optical is a health-retail hybrid; the "other" bin is an atomistic, mostly-private franchise-and-roll-up economy. The rollup's real value is the contrast, so that is where we start.

Acronyms used throughout are defined on first use. Company names, tickers, and financials are reserved to Sections 4 and 10, per house style.

---

2. What's inside — the four children and how they differ

The four children are not scaled-down copies of one another; they are four distinct economies that happen to share a shelf in the federal classification. The table contrasts them on the axes that actually change how you would own each one.

PBM = pharmacy benefit manager (the middleman that sets pharmacy pay); DTC = direct-to-consumer; HME = home medical equipment; PE = private equity.

How to read the contrast — four takeaways:

1. One child is the market. Pharmacies are ~83% of the dollars, so when a headline says "health and personal care retail did X," it is overwhelmingly saying something about drugstores. The level's growth, margins, and closures are mostly the pharmacy story [2][9].
2. They travel in opposite directions. Drugstores and supplement specialty stores are closing or ceding share; beauty stores and hearing/HME are opening or expanding. A weak quarter for CVS tells you nothing about Ulta or a Miracle-Ear center — different customers, different economics [2][3][5].
3. Ownership is where the real divergence lives. Beauty has clean listed pure-plays; pharmacy has almost none left; optical and the "other" bin are private, private-equity, or foreign-listed. So the four children are not just different businesses — they are reachable through completely different instruments (Section 4).
4. Concentration is a pharmacy artifact. The level looks moderately concentrated only because pharmacies are, and pharmacies are 83% of it. The other three children run from a beauty "barbell" to a near-atomistic "other" bin (Section 3).

---

3. Size (this level's rollup figures)

Our ground-truth federal statistics for NAICS 4561 come from the 2022 Economic Census concentration file [1]. That file gives us receipts, firm count, and concentration ratios for the level — but not establishment counts, employment, or payroll; those we sum up from the four child primers (County Business Patterns 2023) and flag as such.

The children reconcile cleanly. Their receipts sum to ~$654.6 billion against the level's $654.6 billion; their firm counts sum to 49,766 against the level's 49,659 (the small ~100-firm gap reflects firms operating in more than one of these industries, counted once at the level). So there is no missing mass here — the level genuinely is its four children added together [2][3][4][5].

Concentration — read it as "pharmacy plus dilution." The HHI (a standard gauge that squares and sums every firm's market share; 10,000 = pure monopoly, and U.S. antitrust convention calls anything under 1,500 "unconcentrated") comes out at 1,186.7 — technically unconcentrated. But that number is deceptive in two ways:

• It sits below the pharmacy child's own HHI of 1,710.8, because blending in three less-concentrated businesses (beauty, optical, and the atomistic "other" bin at HHI 63) mathematically dilutes any single firm's share of the whole. The level looks less concentrated than its dominant child [1][2].
• Yet the level's top four firms take 59% of all receipts — and those four are essentially the top four drug chains. (The pharmacy child's CR4 of 71% applied to its 83% share of the level lands almost exactly at the level's 59% CR4.) In other words, a handful of pharmacy giants sit atop a group of nearly 50,000 firms [1][2].

So the honest reading is: the top of this industry group is an oligopoly of drug chains; the tail is a vast, fragmented long tail of independents across beauty-supply shops, opticians, vitamin stores, and hearing/medical-supply dealers.

Undercount caveat — large, and it runs the same direction in every child. The $654.6 billion is a specialty-storefront register, not the size of the underlying consumer economy for these goods. Each child leaks enormous volume to codes outside 4561:

• Channel leakage to mass/grocery/online. Prescriptions filled at Walmart, Costco, and Kroger; beauty bought at Target, Amazon, and department-store counters; optical departments inside warehouse clubs; supplements sold at every drugstore and club — all are booked under their host store's code, not here. Counting prescriptions across all channels alone puts U.S. dispensing revenue near $683 billion (vs. the $544 billion drugstore slice) [9], and broader trade estimates for beauty (~$69B), optical (~$70B), and supplements (~$60–73B) each run well above the specialty-store figure in this table [11][12].
• Leakage to health-care service codes. Optometrists' and ophthalmologists' offices, pharmacy benefit managers, and the durable-medical-equipment (DME) billers that invoice Medicare and insurers are classified as health-care services or rental, not retail [4][5].
• Nonemployer / small-owner undercount. County Business Patterns counts only employer businesses. In the fragments where small or individual ownership dominates — independent opticians, one-person medical-supply and hearing shops, tiny vitamin stores — the smallest solo operators fall below the line. This undercount is most material in 45613 and 45619, less so in the chain-heavy pharmacy child [4][5].

Net: treat $654.6 billion as roughly the brick-and-mortar specialty slice, materially smaller than what Americans actually spend on medicines, beauty, eyewear, supplements, and home-medical goods across all channels. The federal file carries no industry-wide same-store-sales, margin, or online-share data, and none is asserted here.

---

4. Investable universe (where value concentrates across the children)

The defining investment fact of this level is that where the value pools — and whether you can buy it at all — differs completely by child. There is no single fund or ticker that cleanly represents NAICS 4561; you assemble exposure child by child.

Three patterns cut across the level:

1. The cleanest listed pure-play in the whole group is a beauty retailer (Ulta), not a pharmacy. Pharmacy — 83% of the dollars — has been stripped of listed pure-plays by consolidation (Rite Aid liquidated, Walgreens went private, and CVS is a conglomerate). So the largest child is the hardest to own directly, and the exposure you can buy is diluted inside insurers and mass retailers [2][3].
2. Two children are only reachable abroad or through private markets. The optical giant EssilorLuxottica and every marquee hearing brand trade (if at all) on European exchanges or sit inside private-equity portfolios. A U.S. investor reaching them takes on foreign-exchange (FX) and foreign-market risk, or must go private [4][5].
3. Product-makers are a different bet than store-owners — in every child. The beauty brand houses (Estée Lauder, e.l.f., Coty), the contact-lens makers (Alcon, Cooper, Bausch + Lomb), the supplement brands (BellRing, Simply Good Foods), and the drug wholesalers are all manufacturing/wholesale codes, not retail. They earn higher gross margins and represent a bet on brands and formulation, not on store retailing [3][4][5].

There is no dedicated NAICS-4561 exchange-traded fund (ETF) or index. Broad retail/consumer-discretionary ETFs hold a few of these names among many, so any packaged exposure is heavily diluted.

---

5. How the money works

Because the children run on genuinely different engines, the honest answer is "it depends which child" — but three of the four share a common shape.

• 45611 Pharmacies — reimbursement retail. A pharmacy buys a drug at an acquisition cost and is reimbursed by a PBM or payer at a contracted rate plus a dispensing fee; gross profit per prescription = (reimbursement − acquisition cost) + fee. The whole industry's stress lives on that line, because the pharmacy rarely controls the final price and PBMs have driven reimbursement down for years. Generics (about nine of ten U.S. prescriptions) carry high percentage margins and are the profit backbone. Profit has migrated out of the store into groups that own both a pharmacy and a PBM [2][9][10].
• 45612 Beauty — spread plus loyalty. Retailers earn the markup between wholesale and retail, amplified by traffic, private label, and in-store services. The core health signal is comparable ("same-store") sales, split into traffic and average ticket; gross margins run high-30s to mid-40s percent. The biggest moat is the loyalty program — tens of millions of members driving repeat visits and co-branded credit-card economics [3].
• 45613 Optical — product plus services plus managed care. Two engines — product (frames, lenses, contacts) and services (exams and fittings via an affiliated optometrist) — layered with memberships and insurance contracts. Frames and lenses carry famously high markups, but rent, licensed labor, marketing, and lab costs eat much of it, leaving ordinary retail operating margins. Contact lenses add lower-margin recurring demand [4].
• 45619 Other — two engines under one code. Supplement retail is high-margin, small-box, repeat-purchase cash retail leaning on private label and auto-ship. Hearing/HME is device margin + service attachment + reimbursement: a several-thousand-dollar hearing aid bundled with clinical fitting, or DME billed to Medicare and insurers, with a resupply annuity (CPAP masks, filters) as the profit engine [5].

The common thread. Setting aside pharmacy's unique reimbursement plumbing, the other three are service- or loyalty-anchored, recurring-aftermarket retail rather than thin-margin fast-moving goods — they defend margin with private label, loyalty, vertical integration, and service attachment against price-transparent online and mass competitors. Across every child, the metrics that matter are comparable-store sales, gross margin and revenue per location, private-label/attachment rate, repeat/resupply rates, and inventory turns — plus, for pharmacy and HME, payer mix and reimbursement. Regulated-utility rate-base, real-estate FFO, and mining-cost frameworks do not apply anywhere in this level; this is retail-plus-service economics.

---

6. Demand drivers

The level's resilience comes from the fact that its four children answer to largely independent demand systems — so a shock to one barely touches the others, and the aggregate is steadier than any single child.

• Pharmacies (45611): an aging, increasingly chronically ill population lifts prescription volume; the GLP-1 (glucagon-like peptide-1) obesity/diabetes-drug boom is a large volume tailwind (though mixed for margin); insurance design (Medicare Part D, Medicaid, commercial) sets affordability; convenience-driven channel shift keeps moving where demand lands [2][9].
• Beauty (45612): product newness (a viral serum or scent can move a quarter), social media — especially TikTok — as the discovery engine, gifting/services, and younger consumers treating beauty as wellness. Relatively recession-resistant ("lipstick effect") but still discretionary [3].
• Optical (45613): aging (near-universal presbyopia after the mid-40s), high sticky penetration (~94% of adults use some eyewear), rising myopia linked to screen time, fashion-driven frame replacement, and a potential smart-glasses upgrade cycle [4].
• Other (45619): supplements ride broad habitual usage (~75% of adults) and wellness fads; hearing/HME rides the dominant, non-cyclical demographic escalator — Americans 65-and-older reached 18% of the population in 2024 — plus chronic-disease prevalence and care moving into the home [5][12][14].

The unifying macro driver is demographics. Aging simultaneously lifts prescriptions, eyewear, hearing aids, and home-medical demand — three of the four children (all but beauty) are direct beneficiaries of the graying U.S. population. Beauty is the one child driven mainly by discretionary confidence and cultural trend rather than age. That mix — three demographic-defensive children plus one culturally-driven discretionary one — is what makes the level as a whole one of retail's more durable.

---

7. Regulation

This is one of the most heavily and variably regulated corners of retail — but the regulatory weight is wildly uneven across the children, and that unevenness is itself an investment fact.

• Pharmacies (45611) — the heaviest, and the most contested. State boards of pharmacy, the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Centers for Medicare & Medicaid Services (CMS, for Part D/Medicaid reimbursement), and the Health Insurance Portability and Accountability Act (HIPAA). The fastest-moving front is PBM and competition policy — the Federal Trade Commission (FTC) has issued interim staff reports on PBM concentration, specialty markups, and spread pricing, and federal/state PBM reforms are phasing in. For dispensers, tighter PBM rules are broadly a potential tailwind [2][10].
• Beauty (45612) — light as retailing, tightening on product. The FDA generally does not pre-approve cosmetics, but the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) — the biggest expansion of FDA cosmetics authority since 1938 — adds facility registration, product listing, and safety-substantiation duties that fall on retailers selling private label. The FTC polices advertising and influencer disclosure [3].
• Optical (45613) — pro-competition retail rules on a medical-device base. The FTC Eyeglass Rule and Contact Lens Rule require prescribers to release prescriptions so shoppers can fill them anywhere; the FDA regulates contact lenses as medical devices; and state corporate-practice laws typically separate the retail company from a physician-owned entity via a management-services organization (MSO) [4].
• Other (45619) — a split regime. Supplements are regulated as food under the Dietary Supplement Health and Education Act of 1994 (DSHEA) — no FDA pre-approval, structure/function claims only, FTC advertising oversight — with a "modernization" wildcard that could tighten the rules. Hearing/HME faces a heavy device-and-reimbursement regime — the 2022 over-the-counter (OTC) hearing-aid rule, and CMS's DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) competitive-bidding program that directly sets prices [5].

The through-line: in the two health-heavy children (pharmacy, hearing/HME), reimbursement policy is the swing factor — cuts squeeze margins, potential new coverage would be a demand step-change. In the two more consumer-facing children (beauty, supplements), regulation is lighter and the risk is that it tightens. Every child carries FTC advertising oversight and product-safety/recall exposure.

---

8. Consolidation

All four children are fragmented at the store level but consolidating at the ownership level — yet they are consolidating toward different owners and for different reasons, which is why the level-wide concentration statistics understate how tightly held each real market is.

• Pharmacies: the most dramatic reshaping of U.S. retail pharmacy in a generation — Rite Aid liquidated, Walgreens went private (Sycamore Partners, 2025), and CVS is the dominant listed chain; the winning structure is vertical integration (pharmacy + PBM); nearly one in three U.S. retail pharmacies has closed since 2010, leaving "pharmacy deserts" [2][13].
• Beauty: a two-horse premium race between Ulta and Sephora, fought partly through shop-in-shop deals inside general retailers, plus international expansion (Ulta's 2025 purchase of the UK's Space NK) and PE/family-office buys of luxury/clean chains [3].
• Optical: shaped by two vertically integrated giants — EssilorLuxottica (manufacturing + brands + retail + insurance) and VSP Vision (largest vision insurer, also a retailer) — with continuing PE roll-ups of independent practices (MyEyeDr, EyeCare Partners, 1-800 Contacts) [4].
• Other: supplements consolidate at the edges (PE re-tooling chains, online mergers, brand M&A), while hearing/HME is being remade by vertical integration — the landmark being Amplifon's ~€2.3 billion agreement to acquire GN Hearing (2026), fusing the world's largest hearing retailer with a top device maker [5].

The unifying dynamic: in every child, the winning consolidators pair stores with either an upstream product engine (a PBM, a lens/device factory, a private-label supplement line) or a payer network — capturing margin the standalone independent cannot. The recurring loser is the single-location, single-line independent squeezed between a price-transparent online channel and a vertically integrated giant that both supplies and competes with it. That squeeze is what keeps feeding consolidation across the whole level.

---

9. Risks

Shared across the level:

• Channel disintermediation. Every child cedes volume to Amazon, Walmart, Costco, and direct/online sellers — the biggest competitive threat in each case sits outside the NAICS code.
• Vertical squeeze. Independents increasingly buy from firms that also own competing retail (PBM-owned pharmacies, device-maker-owned hearing chains, private-label supplement chains) — a structural pressure on the fragmented tail.
• Fixed-cost store networks losing leverage as sales shift to mail/online, plus labor and licensed-professional shortages (pharmacists, opticians, audiologists).
• Product safety, recall, and liability exposure that can land on the retailer even when manufacturing is outsourced — heaviest for private label.
• Private-company opacity and measurement risk. Much of the level is private, PE-owned, or foreign-parent-owned; and federal data undercount nonemployers and route huge volumes to other codes, so headline figures understate the real markets.

Concentrated by child:

• Pharmacy: reimbursement compression (the central risk), PBM leverage and vertical conflicts, regulatory whipsaw, GLP-1 margin dilution, and legacy liabilities (opioid settlements were fatal to Rite Aid) [2].
• Beauty: discretionary/cyclical sensitivity, loss of brand exclusivity, trend/inventory risk, theft (small high-value goods), and tariff/supply-chain cost on imports [3].
• Optical: consumer sensitivity on deferrable big-ticket purchases, payer pressure from two dominant vision networks, optometrist shortages, tariffs on China-made frames, and long-run substitution from refractive surgery [4].
• Other: supplement regulatory tightening and trade-down risk plus foreign-state ownership scrutiny (GNC); hearing/HME reimbursement risk in both directions, billing-compliance exposure, and FX/foreign-listing risk on the European hearing names [5].

---

10. How to invest, and the outlook

The signature of NAICS 4561 for an investor is that the four children are reachable through four different instruments — and the biggest child is the hardest to own directly. Practical menu, by route:

Public-market routes (largely indirect):

1. Beauty (45612) offers the cleanest listed pure-play in the whole level — Ulta (ULTA), with Sally (SBH) the smaller-cap value angle. This is the one place a general investor can buy the store itself [3].
2. Optical (45613) via EssilorLuxottica (the diversified way to own the value chain), National Vision (EYE) (the clearest U.S. pure-play), and Warby Parker (WRBY) (DTC growth with smart-glasses optionality) [4].
3. Pharmacy (45611) — 83% of the dollars but mostly indirect. CVS Health is the only large listed pure-play and must be analyzed segment-by-segment (prescription volume, reimbursement per script, gross margin after PBM adjustments, generic/specialty mix, lease and debt load); broader exposure runs through insurer-PBMs (Cigna, UnitedHealth) and pharmacy-carrying retailers (Walmart, Kroger, Costco, Amazon) [2].
4. Other (45619) — proxies only. The most direct listed exposure is foreign — European hearing groups Amplifon, Sonova, Demant, GN — plus U.S. home-medical billers AdaptHealth (AHCO) and Accendra (ACH), and supplement proxy grocer Natural Grocers (NGVC) [5].

Compare names within each child on comparable-store sales, transaction and ticket growth, gross margin, private-label/attachment share, inventory turns, resupply/repeat rates, payer mix and days sales outstanding (for pharmacy and HME), leverage, and free cash flow — and value on price-to-sales or enterprise-value-to-EBITDA (earnings before interest, taxes, depreciation, and amortization) only after adjusting for how little of each business is actually this NAICS code.

Private-market routes (the direct exposure): across three of the four children, direct ownership of the storefront is a private, franchise, or roll-up decision — an independent community pharmacy, a beauty-supply or optical store, a franchised hearing center, or a PE-backed roll-up of any of these. The Small Business Administration (SBA) size standards vary by child (from $9.5M in the "other" bin to $37.5M for pharmacies), and most operators fall under them — this is, at the tail, a small-business economy. Diligence what headline revenue hides: reimbursement and payer contracts (pharmacy, HME), lease and private-label economics (supplements, beauty), exam conversion and corporate-practice compliance (optical), and inventory/aged-stock across all [2][3][4][5][15].

Outlook (forward-looking judgment; the federal data carry no forecast, so no growth rate is asserted). The level is best understood as four clocks running at different speeds:

• Pharmacy — prescription volume keeps growing with demographics and new drugs, but the value of dispensing keeps concentrating in vertically integrated PBM-pharmacy platforms and lower-cost mass/grocery/online channels; the standalone corner drugstore stays under the most durable pressure, its fate hinging on reimbursement policy [2].
• Beauty — steady low-single-digit category growth with fragrance and skincare leading, prestige/mass convergence favoring broad-assortment chains, and physical stores staying resilient because sampling resists digitization [3].
• Optical — a durable, slow-moving demographic base, with value/DTC formats taking share from full-price chains and smart glasses the genuine wildcard [4].
• Other — two-speed: supplement specialty stores keep ceding share to online/mass while the category stays healthy, and hearing/HME is the steadier, demographically-floored half; watch the Amplifon–GN integration and any movement on Medicare hearing coverage [5].

For most public investors the practical exposure is therefore a mosaic — a beauty pure-play, a pharmacy conglomerate, an optical giant, and a foreign hearing group — because no single instrument captures "health and personal care retail." That the largest child (pharmacy) is nearly un-buyable as a pure play, while the smallest quadrant offers the cleanest ones, is the defining irony of NAICS 4561.

For the full treatment of each child — company-by-company tables, unit economics, the complete regulatory map, deal histories, and diligence checklists — see the leaf primers for 45611, 45612, 45613, and 45619.

---

Sources

1. U.S. Census Bureau, 2022 Economic Census — Concentration of Largest Firms, NAICS 4561 (our ground-truth file: receipts $654.6B; 49,659 firms; CR4 59.0% / CR8 64.6% / CR20 70.0% / CR50 74.1%; HHI 1,186.7). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
2. Histometrics primer, NAICS 45611 — Pharmacies and Drug Retailers (child primer; synthesizes 2022 Economic Census, County Business Patterns, IQVIA, Drug Channels, FTC PBM reports, SEC filings, and consolidation reporting).
3. Histometrics primer, NAICS 45612 — Cosmetics, Beauty Supplies, and Perfume Retailers (child primer; synthesizes 2022 Economic Census, County Business Patterns, SBA size standards, MoCRA, and SEC filings/IBISWorld).
4. Histometrics primer, NAICS 45613 — Optical Goods Retailers (child primer; synthesizes 2022 Economic Census, County Business Patterns, The Vision Council, FTC Eyeglass/Contact Lens Rules, and SEC filings).
5. Histometrics primer, NAICS 45619 — Other Health and Personal Care Retailers (child primer; synthesizes 2022 Economic Census, County Business Patterns, CRN/Ipsos, CMS, FDA OTC hearing rule, and hearing/HME M&A reporting).
6. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms for children 45611, 45612, 45613, 45619 (firms, receipts, CR4/CR8/CR20/CR50, HHI). https://data.census.gov/table/ECNSIZE2022.EC2200SIZECONCEN
7. U.S. Census Bureau, County Business Patterns, 2023 — establishments, employment, payroll for the four children (level figures summed from the child primers; not present in our level file). https://www.census.gov/programs-surveys/cbp.html
8. U.S. Census Bureau, 2022 NAICS Manual — definitions and scope for 4561 and its children, and the 2017→2022 retail reorganization. https://www.census.gov/naics/reference_files_tools/2022_NAICS_Manual.pdf
9. IQVIA Institute, The Use of Medicines in the U.S. 2024/2025, and Drug Channels Institute, Top 15 U.S. Pharmacies of 2024 (all-channel dispensing near $683B; ~7.1B retail scripts). https://www.iqvia.com/insights/the-iqvia-institute
10. U.S. Federal Trade Commission, Interim Staff Reports on Prescription Drug Middlemen (2024–2025; PBM concentration, specialty markups, spread pricing). https://www.ftc.gov/news-events
11. The Vision Council, Market inSights 2025, and IBISWorld beauty-retail estimates (broader optical and beauty market sizes above the specialty-store slice). https://www.ibisworld.com/united-states
12. Council for Responsible Nutrition / Ipsos, 2024 Consumer Survey (~75% of adults use supplements), with Nutrition Business Journal supplement-sales estimates (~$60–73B). https://www.crnusa.org/newsroom
13. Walgreens Boots Alliance / Sycamore Partners (private in 2025); Rite Aid liquidation (2025); USC Schaeffer Center / Health Affairs, pharmacy closures since 2010. https://corporate.walgreens.com/news-and-stories
14. U.S. Census Bureau, Older Adults (65+ = 18.0% of population, 2024) and 85+ projections. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
15. U.S. Small Business Administration, Table of Size Standards (2023) — per-industry receipts thresholds for 45611/45612/45613/456191/456199 (classification rules, not market-size estimates). https://www.sba.gov/document/support-table-size-standards